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Background. Pseudomonas aeruginosa (Pa) is the most important pathogen infecting the airways in individuals
with cystic fibrosis. A key question is whether children with newly acquired Pa infection who are able to achieve
sustained eradication after early antipseudomonal therapy demonstrate improved long-term health outcomes com-
pared with those who are unable to achieve a sustained microbiologic response.
Methods. This cohort study utilized observational follow-up data on children participating in the Early Pseudo-
monas Infection Control trial who received standardized therapy for newly acquired Pa. Sustained eradicators were
defined as those who maintained Pa-negative cultures for 12 months after initial antipseudomonal therapy. Associ-
ations between eradication status and outcomes were assessed.
Results. Of the 249 trial participants included in the study, 172 (69%) achieved sustained eradication of Pa dur-
ing the trial (sustained eradicators). Over the median 5-year follow-up, sustained eradicators had a 74% reduced risk
of developing chronic Pa (hazard ratio [HR], 0.26; 95% confidence interval [CI], .17–.40) and a 57% reduced risk of
mucoidy (HR, 0.43; 95% CI, .25–.73) compared with nonsustained eradicators. Sustained eradicators had signifi-
cantly less anti-Pa antibiotic usage during follow-up compared with nonsustained eradicators. There was no asso-
ciation between eradication status and clinical outcomes including rate of exacerbation and lung function decline.
Conclusions. This is the first study to quantify the long-term durability of microbiological response associated
with early antipseudomonal therapy, demonstrating the critical importance of optimizing antipseudomonal thera-
pies during early Pa infection. The clinical impact of failure to achieve sustained Pa eradication remains unclear,
however, and may be confounded by anti-Pa antibiotic usage.
Clinical Trials Registration. NCT00097773.
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Pseudomonas aeruginosa (Pa) is perhaps the most im-
portant pathogen infecting the airways of individuals
with cystic fibrosis (CF) [1, 2]. Early antibiotic treatment
of newly acquired Pa, regardless of the presence of accom-
panying symptoms, is now considered standard of care
to rapidly clear the pathogen and delay establishment of
chronic infection [1, 3, 4]. However, the long-term im-
pact of early antipseudomonal antibiotics on the pro-
gression of disease remains unclear. The majority of
studies to date have focused on the comparison of clin-
ical outcomes between those newly vs never infected
with Pa [2, 5–9]; however, there is now a need to shift
our efforts and determine the long-term clinical impact
of current antipseudomonal treatment approaches for
new Pa. A key clinical question is whether individuals
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with new Pa who are able to successfully achieve sustained Pa
eradication after early antipseudomonal therapy at the time of
new Pa acquisition demonstrate improved outcomes compared
with those unable to achieve sustained eradication.
Consistent data across recent multicenter studies suggest that
approximately one-third of children with CF and newly ac-
quired Pa will fail to achieve sustained Pa eradication over a
1- to 2-year period after initial antipseudomonal therapy [10,
11], and yet there are limited data over a long duration of fol-
low-up to quantify how their clinical progression of disease is
affected. The Early Pseudomonas Infection Control (EPIC) clin-
ical trial randomized children aged 1–12 years with newly ac-
quired Pa to assess the efficacy of more aggressive vs less
aggressive antipseudomonal therapy, and demonstrated no sig-
nificant differences in outcomes between treatment regimens
[10]. These children have been closely monitored for >5 years
in an ongoing observational study, providing a unique opportu-
nity to investigate the long-term impact of sustained Pa eradi-
cation [12].
The objectives of this study were to characterize Pa recur-
rence patterns among a contemporary cohort treated for
newly acquired Pa and to compare those who achieved sus-
tained eradication during the clinical trial with those who did
not in terms of long-term microbiologic and clinical outcomes
after completion of the clinical trial. We hypothesized that chil-
dren who achieved sustained Pa eradication had a reduced risk
of chronic Pa infection and mucoid Pa acquisition, reduced pul-
monary exacerbation rates, and less rapid pulmonary function
decline compared with participants who were unable to achieve
sustained Pa eradication.
METHODS
Study Cohort and Definition of Sustained Eradication at Trial
Completion
The cohort was comprised of participants from the EPIC Clin-
ical Trial (ClinicalTrials.gov identifier NCT00097773) [10] who
consented for follow-up in the EPIC observational study [12].
Figure 1. Overview of study design. Children with cystic fibrosis (CF) aged 1–12 years with newly identified Pseudomonas aeruginosa (Pa) infection within
6 months of enrollment were eligible for the trial. Newly identified Pa was defined as the first lifetime documented Pa-positive culture or a Pa-positive
culture after a 2-year absence of Pa culture positivity (requiring at least 1 culture per year). For children aged 12–15 months, at least 1 Pa-positive culture
since birth was required. Other eligibility criteria have been previously reported [12]. During the first quarter of the study, all children received initial Pa
eradication treatment consisting of tobramycin inhalation solution, with half of the children randomly assigned to a concurrent course of oral ciprofloxacin
and half to oral placebo. Children were randomized to 1 of 2 maintenance treatment strategies: (1) cycled therapy—treatment provided in quarterly cycles
regardless of findings from scheduled quarterly respiratory cultures; or (2) culture-based therapy—treatment only in response to identification of Pa from
quarterly cultures. Sustained Pa eradication was based on the Leeds definition of “Pa-free” [13] and required participants to have been Pa culture negative
for at least 12 months prior to the completion of the trial (based on cultures obtained quarterly, with the average number of cultures for the cohort in the 12
months of the trial equal to 4.7). The assessment period for defining sustained Pa eradication allowed up to 6 prior months of intensive antipseudomonal
therapy to achieve initial Pa eradication and was defined during the maintenance therapy phase of the trial. Long term follow-up was provided via the Early
Pseudomonas Infection Control (EPIC) observational study and the CF National Patient Registry.
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Key eligibility criteria and treatment received during the trial are
shown in Figure 1 and have been previously described [12]. Par-
ticipants were defined as “sustained eradicators” upon comple-
tion of the 18-month clinical trial if all quarterly cultures
obtained during the preceding 12 months were free of Pa
(Leeds definition of “Pa-free”) [13]. This study was approved
by the Institutional Review Board at Seattle Children’s Hospital,
Seattle, Washington.
Microbiologic and Clinical Outcomes After Trial Completion
Respiratory cultures during follow-up were performed at site
clinical microbiology laboratories as part of standard clinical
care, with results recorded in the Cystic Fibrosis Foundation
National Patient Registry (CFFNPR). Microbiologic endpoints
included time to first and second Pa recurrence and time to
chronic Pa, defined as the third quarter in which a Pa-positive
culture was observed within a 2-year period, which included ret-
rospectively assessing cultures during the clinical trial period as
applicable for earlier cultures during the follow-up period [14].
Time to mucoidy and resistant Pa were defined, respectively, as
the first quarter in which a mucoid or resistant Pa culture was
recorded in the CFFNPR since trial completion.
Clinical outcomes included antibiotic usage and rate of pul-
monary exacerbations as defined by the physician and requiring
home intravenous antibiotics or hospitalization. Exacerbations
were counted as unique events if separated by at least 21 days.
Antibiotic therapy received during the follow-up period was
recorded at each clinical care episode. The forced expiratory
volume in 1 second (FEV1) was recorded among those old
enough to perform spirometry and expressed as a percentage
of predicted [15, 16].
Statistical Methods
Multivariable regression models included eradication status as
the primary predictor, with a priori adjustment for age at com-
pletion of the trial, lifetime Pa history (never infected vs a history
of Pa positivity >2 years prior to the start of the trial), and treat-
ment received during the trial (cycled vs culture-based therapy).
Further details can be found in the Supplementary Data.
RESULTS
Overview of the Study Cohort at Trial Completion
Of the 304 participants randomized into the EPIC trial, 249 (82%)
completed the trial and continued in the EPIC observational
study. Of these, 172 (69%) achieved sustained eradication of Pa
during the trial (“sustained eradicators”) and 77 (31%) failed to
achieve sustained Pa eradication and had at least 1 recurrence
of Pa within the last year of the trial (“nonsustained eradicators”).
The mean age of the cohort at the end of the trial was 7.2
years, and average FEV1% predicted was 97.7% (Table 1). No
clinical characteristics significantly distinguished the sustained
eradicators and nonsustained eradicators. The 55 trial partici-
pants not included in our study due to lack of follow-up data
were younger than those in our cohort and had slightly lower
FEV1% predicted (Supplementary Table E1). Consistent with
results from the trial [10], more participants on cycled therapy
achieved sustained eradication (93/172 [54%]) compared with
those on culture-based therapy (29/77 [38%]) (16% difference;
95% confidence interval [CI], 3%–29%); however, the majority
of participants in the culture-based therapy group responded to
subsequent antibiotic therapy so that the prevalence of positive
Pa cultures at the end of the trial was the same between the cy-
cled and culture-based groups (10% vs 11%, respectively).
Pa Recurrence Patterns After Completion of the Trial
The median follow-up time of the study cohort after completion
of the study was 5.0 years (range, 0.3–6.6 years), with sustained
eradicators having a slightly greater median follow-up time than
nonsustained eradicators (5.1 vs 4.9 years, respectively). Overall,
adherence to quarterly cultures during follow-up was high in
this cohort, with 85% of 3995 total follow-up quarters having
≥1 culture result available; culture frequency was comparable
between sustained eradicators and nonsustained eradicators
(85% vs 84% of follow-up quarters with ≥1 culture result,
respectively).
Over the follow-up period, 65 of 77 (84%) of the nonsus-
tained eradicators vs 103 of 172 (60%) of the sustained eradica-
tors experienced ≥1 Pa recurrence (Table 2). The median time
to first Pa recurrence was 3.5 years among the sustained eradi-
cators vs only 1 year among the nonsustained eradicators (a
58% reduction: hazard ratio [HR], 0.42; 95% CI, .3–.57). Treat-
ment received during the trial was not significantly associated
with Pa recurrence during follow-up.
Among those with a recurrence of Pa, 55% of the 103 sus-
tained eradicators and 77% of the 65 nonsustained eradicators
had a second recurrence of Pa during the follow-up period.
Among those with a first Pa recurrence, the median time to sec-
ond recurrence was 2.0 and 0.75 years for the sustained and
nonsustained eradicators, respectively (HR, 0.55; 95% CI,
.38–.81; Table 2).
Association Between Sustained Eradication and the
Development of Chronic and Mucoid Pa
Whereas 56% of the 77 nonsustained eradicators developed
chronic Pa infection during follow-up after a median of 3.25
years, only 23% of the 172 sustained eradicators developed
chronic Pa infection (33% difference; 95% CI, 20%–45%). As
shown in Table 3 and Figure 2A, sustained eradication during
the trial was associated with a 74% reduced risk of development
of chronic Pa infection (HR, 0.26; 95% CI, .17–.40), even after
adjustment for potential confounders. Increasing age and
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lifetime history of Pa positivity were significantly associated
with the risk of development of chronic Pa infection. Interest-
ingly, use of cycled therapy during the trial was also associated
with increased risk of the development of chronic Pa infection
during the follow-up period.
Over the course of follow-up, 33% of the 77 nonsustained
eradicators vs 17% of the sustained eradicators presented
with mucoid Pa (16% difference, 95% CI, 4%–28%). Sustained
eradication was associated with a 57% reduced risk of the ap-
pearance of mucoid Pa over the follow-up period (HR, 0.43;
95% CI, .25–.73; Figure 2B). In multivariable modeling, in-
creased age and lifetime history of Pa positivity were also as-
sociated with increased risk of mucoid Pa, although use of
cycled therapy during the trial was not (Table 3). Of the 168
participants with Pa recurrence, only 25 (15%) had at least 1
Pa isolate recorded as resistant to either aminoglycosides,
quinolones, or β-lactams during the follow-up period, and
these participants were comparably distributed by eradication
status and use of cycled or culture-based therapy during the
trial.
Table 1. Study Cohort Characteristics
Characteristic
Nonsustained
Eradicator (n = 77)
Sustained
Eradicator (n = 172)
Total
(N = 249) P Value
Sex
Female 40 (51.9%) 86 (50.0%) 126 (50.6%) .776
Age at trial completion, y
Mean (SD) 7.6 (4.1) 7.0 (3.3) 7.2 (3.6) .308
Age at trial completion .079
<6 y 35 (45.5%) 79 (45.9%) 114 (45.8%)
6 to <10 y 17 (22.1%) 57 (33.1%) 74 (29.7%)
≥10 y 25 (32.5%) 36 (20.9%) 61 (24.5%)
Race .443
White 75 (97.4%) 163 (94.8%) 238 (95.6%)
Hispanic 1 (1.3%) 1 (0.6%) 2 (0.8%)
African American . . . 5 (2.9%) 5 (2.0%)
Unknown/other 1 (1.3%) 3 (1.7%) 4 (1.6%)
Genotype .928
F508 del homozygous 42 (54.5%) 88 (51.2%) 130 (52.2%)
F508 del heterozygous 28 (36.4%) 64 (37.2%) 92 (36.9%)
Othera 4 (5.2%) 12 (7.0%) 16 (6.4%)
Unknown 3 (3.9%) 8 (4.7%) 11 (4.4%)
FEV1% predicted at trial completion
No. 46 106 152
Mean (SD) 98.0 (18.4) 97.6 (15.9) 97.7 (16.6) .895
FEV1% predicted distribution at trial completion .708
<75% 3 (3.9%) 8 (4.7%) 11 (4.4%)
75% to <100% 21 (27.3%) 55 (32.0%) 76 (30.5%)
≥100% 22 (28.6%) 43 (25.0%) 65 (26.1%)
Pa history prior to trial enrollment .236
No lifetime history of Pa positivity 56 (72.7%) 112 (65.1%) 168 (67.5%)
Lifetime history of Pa positivity 21 (27.3%) 60 (34.9%) 81 (32.5%)
Treatment regimen received during the trial .017
Cycled therapy 29 (37.7%) 93 (54.1%) 122 (49.0%)
Culture-based therapy 48 (62.3%) 79 (45.9%) 127 (51.0%)
Oral treatment (in addition to TIS) received during the trial .394
Placebo 43 (55.8%) 86 (50.0%) 129 (51.8%)
Ciprofloxacin 34 (44.2%) 86 (50.0%) 120 (48.2%)
Data are presented as No. (%) unless otherwise specified.
Abbreviations: FEV1, forced expiratory volume at 1 second; Pa, Pseudomonas aeruginosa; SD, standard deviation; TIS, tobramycin inhalation solution.
a Other refers to participants with 2 non-F508 del CFTR mutations.
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Association Between Eradication and Long-term Clinical
Outcomes
Overall, sustained eradicators had 50%–60% less usage of in-
haled antibiotics and oral quinolones over the follow-up period
compared with nonsustained eradicators, and comparable rates
of macrolide usage (Supplementary Table E2). A total of 102
(59%) sustained eradicators vs 60 (78%) nonsustained eradica-
tors recorded use of chronic inhaled antibiotics during the fol-
low-up period, with median times to use of 3.61 and 0.79 years,
respectively (HR, 0.52; 95% CI, .38–.72).
Of the 172 sustained eradicators, 48% had ≥1 pulmonary ex-
acerbation during the follow-up period compared with 45% of
the 77 nonsustained eradicators; event rates were comparable be-
tween sustained eradicators and nonsustained eradicators (rate
ratio, 0.86; 95% CI, .54–1.34; Table 4). In multivariable regression
modeling, female sex was significantly associated with exacerba-
tion rate. Multivariable modeling did not include FEV1% predict-
ed due to a significant proportion of children too young for
spirometry at the beginning of the follow-up period (38% of
the cohort); however, among participants with spirometry, sim-
ilar available findings were observed (Supplementary Table E3).
Additional sensitivity analyses were performed to assess risk of
exacerbations among nonsustained eradicators with more fre-
quent recurrence of Pa during the trial, and although there was
a trend toward an increased risk of exacerbations in this subco-
hort compared with the sustained eradicators, this result was not
statistically significant (Supplementary Table E4).
Pulmonary function remained remarkably stable over the fol-
low-up period, and the average rate of change in FEV1% pre-
dicted in the study cohort was only −0.1% per year (95% CI,
−.8% to .7%). After adjusting for potential confounders, the
rate of change in FEV1% predicted did not significantly differ
between sustained eradicators (0.60% average increase per
year; 95% CI, −2.18% to 3.39%) and nonsustained eradicators
(−0.41% average decrease per year; 95% CI, −1% to .2%).
DISCUSSION
Our study represents the largest prospective study to date as-
sessing long-term microbiologic and clinical outcomes among
a cohort receiving standardized antipseudomonal therapy for
newly acquired Pa. Prior studies have reported robust microbi-
ologic response to early antipseudomonal therapy [3], and in
the largest and longest eradication studies, EPIC [10] and
ELITE [11], approximately 70% of children remained Pa culture
negative in response to therapy for at least 18 to 27 months, re-
spectively. Our study extends these results to show that for the
majority of patients who are able to achieve sustained eradica-
tion as defined by Pa culture negativity throughout the final 12
months of the EPIC trial, the median time to subsequent Pa re-
currence was an additional 3.5 years. Moreover, only 23% of
those who achieved sustained eradication developed chronic in-
fection over a median 5-year follow-up period, and only 17%
developed mucoid Pa. Whereas prior studies have demonstrat-
ed a delay in chronic and mucoid Pa infection with early anti-
pseudomonal therapy in comparison to no therapy [17–19], our
study demonstrates a significantly increased risk of chronic and
mucoid Pa among children who fail to achieve sustained erad-
ication despite receiving antipseudomonal therapy. Although
there is increased relative risk of these poor microbiologic out-
comes among nonsustained eradicators, it is important to note
that the absolute risk specifically for mucoid Pa remains low in
this subcohort, with only 33% developing mucoid Pa during the
median 5-year follow-up period.
In the original EPIC trial, slightly more participants who re-
ceived cycled therapy achieved sustained eradication compared
with those who received culture-based therapy. Our current
study shows that those who received cycled therapy were at in-
creased risk for the development of chronic infection. This sug-
gests the potential that cycled antipseudomonal therapy may
have been suppressing Pa culture positivity during the trial in
Table 2. Time to First and Second Pseudomonas aeruginosa Recurrence After Completion of the Clinical Trial, by Eradication Status
Recurrence
Nonsustained
Eradicator (n = 77)
Sustained






Participants with at least 1 Pa recurrence,
No. (%)
65 (84.4) 103 (59.9) 168 (67.5) Difference, 24.5%
(12.5%–34.4%)
Median time, y, to first recurrence (95%CI) 1.0 (.75–1.75) 3.5 (2.75–4.75) 2.75 (2.50–3.50) HR, 0.42 (.30– .57)
Second Pa recurrence
Participants with at least 2 Pa recurrences,
No. (%)a
50 (76.9) 57 (55.3) 107 (63.7) Difference, 21.6%
(6.8%–34.5%)
Median time, y, to second recurrence
since first recurrence (95% CI)
0.75 (.5–1.5) 2.00 (1.25–3.5) 1.50 (1.0–2.0) HR, 0.55 (.38–.81)
Abbreviations: CI, confidence interval; HR, hazard ratio; Pa, Pseudomonas aeruginosa.
a Denominator is the number of subjects with at least 1 Pa recurrence.
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some children, and because there was no evidence suggesting
that these children remained on cycled therapy after the trial,
that cessation of this therapy may have increased their risk for
Pa recurrence. Thus, there remains no evidence for the benefit
of cycled therapy over culture-based therapy with respect to
long-term microbiologic outcomes.
The long-term health impact of new Pa acquisition remains
unclear, particularly in the era of early antipseudomonal thera-
py. Those who failed to achieve sustained eradication had
strikingly greater antibiotic usage than sustained eradicators,
which may have confounded any comparisons between these
groups. Overall, our study cohort remained relatively healthy,
with approximately half of our cohort not experiencing a single
pulmonary exacerbation requiring intravenous antibiotics or
hospitalization during the median 5-year period, and the aver-
age rate of decline in FEV1 in the cohort was only −0.1% per
year. Importantly, there were no differences in clinical outcomes
between those who achieved sustained eradication vs those who
did not. There are several potential explanations for this finding.
First, as evidenced in placebo-controlled clinical trials for estab-
lished Pa infection [20, 21] that demonstrate improved clinical
efficacy with administration of antipseudomonal therapy, it is
possible that antipseudomonal therapy administered during
early and intermittent infection is also having a positive impact
on outcomes such as exacerbations and lung function that keep
the nonsustained eradicators from declining in health despite
recurrence of Pa. Second, contemporary cohorts such as the
one in this study may be managing their Pa infection better be-
cause of advancing improvements in the management of CF, in-
cluding better nutritional management and the adoption of
several new therapies into the standard of care [21–25]. Last,
as opposed to explanations focused on the host, it is possible
that Pa itself is less pathogenic during initial and intermittent
infection [9], and only has significant detrimental impact
when chronic infection is established and upon increasing bac-
terial density in the airways.
Our findings of a lack of association between microbiologic
response to early eradication therapy and clinical outcomes
may also be explained by factors related to our study design.
The median follow-up time of our cohort was 5 years; this
may not have been a long enough period to assess outcomes re-
lated to the transition to chronic and mucoid Pa. Our study was
also restricted to the definition of exacerbation recorded in the
CFFNPR, representing more severe events requiring intrave-
nous antibiotics or hospitalization. It is possible that there is a
more measurable impact of sustained eradication on more mild
exacerbations treated with oral or inhaled antibiotics. Although
limited data collection was available in the follow-up study to
quantify this, a suggestion that sustained eradication was asso-
ciated with reduced frequency of more mild respiratory events is
reflected in the significantly reduced rates of antibiotic usage
among the sustained eradicators vs the nonsustained eradica-
tors. Lack of sensitive outcome measures to capture decline in
health in children with CF additionally remains a critical prob-
lem, and it is likely that FEV1 is not a sensitive measure. Al-
though one study has suggested that individuals who have
cleared Pa after initial therapy have poorer lung function than
those who had never been infected [8], recent studies have sug-
gested that lung function does not deteriorate after new Pa ac-
quisition in the presence of antipseudomonal treatment [5, 9].
Table 3. Results From Univariate Unadjusted and Multivariable
Adjusted Cox Proportional Hazards Models for the Association
Between Eradication Status and Time to Chronic and Mucoid
Pseudomonas aeruginosa
Variable HR 95% CI
P
Value
Time to chronic Pa (unadjusted)
Nonsustained eradicator . . . . . . . . .
Sustained eradicator 0.26 (.17–.40) <.001
Time to chronic Pa (adjusted multivariable model)
Nonsustained eradicator . . . . . . . . .
Sustained eradicator 0.21 (.13–.33) <.001
Age at trial completion
<6 y . . . . . . . . .
6 to <10 y 1.31 (.73–2.36) .359
≥10 y 1.78 (1.00–3.19) .052
Pa history prior to trial enrollment
No lifetime history of Pa positivity . . . . . . . . .
Lifetime history of Pa positivity 1.69 (1.01–2.82) .046
Treatment regimen received during the
trial
Culture-based therapy . . . . . . . . .
Cycled therapy 1.60 (1.02–2.53) .042
Time to mucoid Pa (unadjusted)
Nonsustained eradicator . . . . . . . . .
Sustained eradicator 0.43 (.25–.73) .002
Time to mucoid Pa (adjusted multivariable model)
Nonsustained eradicator . . . . . . . . .
Sustained eradicator 0.36 (.20–.63) <.001
Age at trial completion
<6 y . . . . . . . . .
6 to <10 y 1.84 (.84–4.00) .126
≥10 y 3.26 (1.52–6.98) .002
Pa history prior to trial enrollment
No lifetime history of Pa positivity . . . . . . . . .
Lifetime history of Pa positivity 1.96 (1.06–3.63) .032
Treatment regimen received during the
trial
Culture-based therapy . . . . . . . . .
Cycled therapy 1.30 (.75–2.26) .345
Abbreviations: CI, confidence interval; HR, hazard ratio; Pa, Pseudomonas
aeruginosa.
712 • CID 2015:61 (1 September) • Mayer-Hamblett et al
Other studies have shown that the decline in lung function oc-
curs only after acquisition of mucoid Pa [26].
There are several notable limitations to our study, including
the restriction of our investigation to a cohort of children newly
diagnosed with Pa. Additionally, there are no standardized def-
initions of eradication, and further work is needed to determine
whether a duration of sustained eradication longer than as-
sessed in this study is associated with better clinical outcomes.
Our study relies heavily on accuracy of culture results, and al-
though this was controlled during the clinical trial [12], this
was not the case during the observational follow-up period.
However, a recent audit was conducted that found excellent
(98.9%) concurrence between microbiologic results recorded
in the CFFNPR vs electronic medical records [27]. Second, it
is possible that sampling approaches utilizing oropharyngeal
swabs and sputum with traditional culture methods are not suf-
ficiently sensitive to accurately characterize early stages of Pa in-
fection in either the lower or upper airways, and thus are unable
to detect underlying infection despite culture negativity for Pa
[28, 29].This approach remains the standard of care in the Unit-
ed States, however, and the prognostic ability of more sensitive
monitoring of infection using serology to predict initial Pa in-
fection, Pa recurrence, and treatment failure has not yet been
demonstrated [30, 31].
In summary, children with sustained eradication after anti-
pseudomonal therapy for newly acquired Pa have significantly
better long-term microbiologic outcomes than those unable to
achieve sustained eradication, including longer times to chronic
and mucoid Pa. The lack of benefit of cycled therapy compared
with culture-based therapy on long-term clinical and microbi-
ologic outcomes continues to support current recommenda-
tions for use of culture-based therapy as an effective approach
for management of early Pa infection [4]. The comparability of
clinical outcomes between those who achieved sustained eradi-
cation vs those who did not suggests that the management of
this entire cohort with the current standard of care has been
successful in maintaining clinical stability with respect to lung
Figure 2. Kaplan–Meier plots of time to chronic Pseudomonas aeruginosa (Pa) infection (A) and time to mucoid Pa infection (B) after completion of the
clinical trial, by eradication status.
Table 4. Association Between Eradication Status and Rate of
Physician-Defined Pulmonary Exacerbations Requiring
Intravenous Antibiotics or Hospitalization During the Follow-up
Period
Rate
Ratio 95% CI P Value
Exacerbation rate (unadjusted)
Nonsustained eradicator . . . . . . . . .
Sustained eradicator 0.86 (.54–1.34) .501
Exacerbation rate (adjusted multivariable model)
Intercept 0.16 (.09–.28) <.001
Nonsustained eradicator . . . . . . . . .
Sustained eradicator 0.85 (.53–1.35) .492
Sex
Male . . . . . . . . .
Female 1.82 (1.19–2.80) .005
Age at trial completion
<6 y . . . . . . . . .
6 to <10 y 1.28 (.77–2.15) .355
≥10 y 1.29 (.74–2.28) .387
Pa history prior to trial enrollment
No lifetime history of Pa positivity . . . . . . . . .
Lifetime history of Pa positivity 1.38 (.86–2.22) .206
Treatment regimen received during the
trial
Culture-based therapy . . . . . . . . .
Cycled therapy 1.37 (.90–2.10) .139
Abbreviations: CI, confidence interval; Pa, Pseudomonas aeruginosa.
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function decline and pulmonary exacerbations requiring intra-
venous antibiotics. Despite this, those who fail to achieve sus-
tained eradication are at greater risk of chronic and mucoid
Pa, and although it is unclear how these key microbiologic end-
points impact subsequent clinical outcomes in an era of aggres-
sive early antipseudomonal therapy, it is imperative that efforts
continue to focus on improving eradication success through
novel therapeutic approaches.
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